AI Diagnostics Raises $4.6M in Pre‑Series‑A Round Led by Steele Foundation for Hope

Why It Matters

The investment fast‑tracks a low‑cost, point‑of‑care TB screening tool, addressing a critical gap in early detection for under‑served populations and potentially reducing transmission across high‑burden regions.

Key Takeaways

• AI Diagnostics raised R85 million (~$4.7 M) for AI stethoscope
• Ostium detects TB signals in real‑time lung sounds
• Device targets nurses, pharmacists, community health workers in low‑resource settings
• AI model trained on a proprietary TB lung‑sound dataset
• Goal: WHO certification and clinic‑wide rollout by 2030

Pulse Analysis

Tuberculosis remains one of the world’s deadliest infectious diseases, with an estimated 10 million new cases annually, most concentrated in low‑ and middle‑income countries. Traditional diagnostics rely on sputum microscopy or chest X‑rays, both of which demand laboratory infrastructure and trained radiologists. AI‑driven point‑of‑care tools are emerging as a solution, offering rapid, scalable screening that can be deployed in community clinics where resources are scarce. By leveraging machine‑learning algorithms that analyze acoustic signatures, innovators are reshaping how TB is detected at the earliest stage.

The Ostium device from AI Diagnostics exemplifies this shift. Built around a digital stethoscope, it captures lung sounds and feeds them into the AI.TB model, a neural network trained on a curated dataset of TB‑positive and negative recordings. The startup’s founders spent years assembling this dataset from diverse settings, ensuring the model can differentiate TB signals even amid background noise, pediatric breath patterns, and co‑infection with HIV. The recent R85 million funding round will fund manufacturing scale‑up, field trials across South Africa, Zambia, and Vietnam, and the rigorous validation needed for World Health Organization pre‑qualification.

Commercially, Ostium competes with AI‑assisted chest‑X‑ray platforms such as CAD4TB and qXR, but it offers a distinct advantage: portability and lower capital expenditure. Health systems can equip frontline workers with a handheld device rather than invest in radiography equipment and maintenance. If WHO certification is secured, the device could become a standard component of primary‑care bundles, accelerating the goal of universal TB screening by 2030. The funding also signals investor confidence in AI‑enabled diagnostics, likely spurring further innovation and partnerships across the broader infectious‑disease landscape.

Deal Summary

Cape Town‑based med‑tech startup AI Diagnostics announced it has closed a pre‑Series‑A funding round of R85 million (≈$4.6 million). The round was led by the Steele Foundation for Hope and will fund deployment of its AI‑powered digital stethoscope Ostium and expansion of the AI.TB model across Africa and Asia.